Rishi Vaswani

Rishi Vaswani has a wealth of experience in the pharmaceutical industry. Rishi began their career in 2003 as a Graduate Student Researcher at the University of California, Irvine, where they accomplished an efficient and convergent strategy for the stereocontrolled total synthesis of (\u2013)-Kaitocephalin, the first naturally occurring glutamate receptor antagonist. Rishi then moved to Merck & Co., Inc. in 2009, where they served as a Senior Research Scientist. In 2011, they joined Constellation Pharmaceuticals as a Scientist I, eventually working their way up to Senior Scientist I. In 2016, they moved to Blueprint Medicines as a Senior Scientist I. In 2018, they joined Foghorn Therapeutics, Inc. as a Principal Scientist and Director. Most recently, in 2021, they joined Recludix Pharma as a Director.

Rishi Vaswani obtained a B.Sc. in Chemistry and a B.Sc. in Biology from UC Irvine between 1995 and 1998. Rishi then went on to pursue a Ph.D. in Organic Chemistry from UC Irvine, which they completed in 2007, with a focus in Synthetic Organic Chemistry.